

Changing Therapeutic Paradigms: Predicting mCRC Lesion Response to Selective Internal Radionuclide Therapy (SIRT) based on Critical Absorbed Dose Thresholds: A Case Study

Kathy P Willowson^{1,2*}, Elizabeth J Bernard², Richard Maher³, Stephen J Clarke⁴, Dale L Bailey^{2,5}

¹ Institute of Medical Physics, School of Physics, University of Sydney, Sydney, Australia

² Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, Australia

³ Department of Radiology, Royal North Shore Hospital, Sydney, Australia

⁴ Department of Medical Oncology, Royal North Shore Hospital, Sydney, Australia

⁵ Faculty of Health Sciences, University of Sydney, Sydney, Australia

ARTICLE INFO

Article type:

Case report

Article history:

Received: 23 Aug 2016

Revised: 2 Nov 2016

Accepted: 6 Nov 2016

Keywords:

Dosimetry

Liver

Response

SIRT

⁹⁰Y

ABSTRACT

A 65 year old male with metastatic colorectal cancer (mCRC) in the liver was referred for selective internal radionuclide therapy (SIRT) following a history of extensive systemic chemotherapy. ⁹⁰Y PET imaging was performed immediately after treatment and used to confirm lesion targeting and measure individual lesion absorbed doses. Lesion dosimetry was highly predictive of eventual response in the follow-up FDG PET performed 8 weeks after therapy. The derived radiation dose map was used to plan a second SIRT procedure aiming to protect healthy liver by keeping absorbed dose below the critical dose threshold, whilst targeting the remaining lesions that had received sub-critical dosing. Again, ⁹⁰Y PET was performed immediately post-treatment and used to derive absorbed dose measures to both lesions and healthy parenchyma. Additional follow-up FDG PET imaging again confirmed the role of the ⁹⁰Y PET dose map as an early predictor of response, and a tool for safe repeat treatment planning.

► Please cite this paper as:

Willowson KP, Bernard EJ, Maher R, Clarke SJ, Bailey DL. Changing Therapeutic Paradigms: Predicting mCRC Lesion Response to Selective Internal Radionuclide Therapy (SIRT) based on Critical Absorbed Dose Thresholds: A case Study. Asia Ocean J Nucl Med Biol. 2017; 5(1): 66-69. doi: 10.22038/aojnmb.2016.7892

Introduction

A 65 year old male with metastatic colorectal cancer (mCRC) in the liver was referred for selective internal radionuclide therapy (SIRT) following a history of extensive systemic chemotherapy. ⁹⁰Y PET imaging was performed immediately after treatment and used to confirm lesion targeting and measure individual lesion absorbed doses. Lesion dosimetry was highly predictive of eventual response in the follow-up FDG PET

performed 8 weeks after therapy. The derived radiation dose map was used to plan a second SIRT procedure aiming to protect healthy liver by keeping absorbed dose below the critical dose threshold, whilst targeting the remaining lesions that had received sub-critical dosing. Again, ⁹⁰Y PET was performed immediately post-treatment and used to derive absorbed dose measures to both lesions and healthy parenchyma. Additional

* Corresponding author: Kathy P Willowson, Department of Nuclear Medicine, Royal North Shore Hospital, St Leonards 2065, NSW, Australia. Tel: +61(2)99264440; Fax: +61(2)99264099; Email: kathy.willowson@sydney.edu.au

© 2017 mums.ac.ir All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

follow-up FDG PET imaging again confirmed the role of the ^{90}Y PET dose map as an early predictor of response, and a tool for safe repeat treatment planning.

Case report

We present the case of a 65 year old male with a history of resection for sigmoid colon cancer in December 2008 and systemic chemotherapy (FOLFOX (5FU + oxaliplatin + leucovorin) + Avastin) over the period April – November 2010. Following resection of a solitary liver lesion in April 2011, he recommenced chemotherapy upon recurrence of hepatic disease in June 2012. Upon further progression, he was referred by the Colorectal Cancer Multi-disciplinary Team (MDT) meeting for consideration of SIRT in May 2014. At the time of SIRT work-up there were no serum indicators of hepatic compromise (bilirubin $12\ \mu\text{mol/L}$ ($<20\ \mu\text{mol/L}$), albumin $40\ \text{g/L}$ ($>30\ \text{g/L}$) and INR normal; WCC $9.9 \times 10^9/\text{L}$; Platelets $252 \times 10^9/\text{L}$; Creatinine $77\ \mu\text{mol/L}$) and no inter-current health issues. A liver-lung shunt of 3.3% was estimated from the $^{99\text{m}}\text{Tc}$ -MAA work-up angiogram, and

SPECT imaging showed good localisation of MAA in all lesions identified on the baseline FDG PET. The “modified BSA method” (Sirtex Medical Ltd, Sydney AUS) was used to prescribe 1.56 GBq of ^{90}Y for treatment, according to a CT-based segmented tumour burden of 1.1% and a 25% dose reduction due to heavy prior chemotherapy (1).

SIRT was performed 6 days after a baseline FDG PET/CT scan. PET imaging of the in vivo therapeutic distribution of [^{90}Y]-SIR-Spheres resin microspheres was acquired 19 hours after implantation, and predicted mean absorbed dose estimates of 6 Gy, 12 Gy, 71 Gy and 60 Gy to the lesions in segments 1, 4a, 5 and 8, respectively. An average of 25 Gy was measured in healthy liver (no area reached 80 Gy, the tolerance level for normal liver quoted in the Sirtex training manual). Follow-up FDG PET was acquired 8 weeks post-SIRT, demonstrating a complete metabolic response for lesions in segment 5 and 8, and stable disease (less than a 50% change in TLG) for lesions in segments 4a and 1 (Figure 1). After further FDG PET imaging in October 2014 indicated progression of disease in the two remaining lesions, a second SIRT treatment




Figure 1. Direct comparison of transverse slices on the baseline FDG PET (upper row), work-up MAA SPECT (second row), ^{90}Y PET derived dose map (third row), and 8 weeks follow-up FDG PET (bottom row) for each of the four lesions identified for SIRT. Lesions receiving an absorbed dose above the critical threshold can be seen to exhibit a complete response at the time of follow-up, whereas those receiving sub-threshold dosing exhibit stable disease




Figure 2. Direct comparison of transverse slices on the baseline FDG PET (upper row), work-up MAA SPECT (second row), ⁹⁰Y PET derived dose map (third row), and 8 weeks follow-up FDG PET (bottom row) for each of the two remaining lesions identified for a second SIRT treatment. The lesion receiving an absorbed dose above the critical threshold can be seen to exhibit a complete response at the time of follow-up, whereas that receiving sub-threshold dosing exhibits stable disease

was performed in November 2014 (1.56 GBq). Dosimetry again was predictive of response, with lesions receiving 88 Gy and 8 Gy demonstrating a complete response and stable disease, respectively, at the time of follow-up in January 2015 (Figure 2). Healthy liver received an average absorbed dose of 21 Gy (a cumulative dose of 46 Gy over both treatments), with a volume of 10% >80 Gy. No hepatic toxicity or indicators of radioembolisation induced liver disease (REILD) (2) were recorded as

of follow-up at 21 months post (second) treatment.

Discussion

⁹⁰Y SIRT relies on preferential perfusion from the hepatic arteries of target lesions within the liver, based on the premise that healthy liver derives the majority of its blood supply from the portal vein, and so should be spared from large absorbed radiation doses. It has only been in recent years with the advent of ⁹⁰Y PET (3) that the localisation of radiation

dose to lesions, and absence in healthy liver or other vulnerable structures (gallbladder, duodenum, etc), can be confirmed post-therapy. The derivation of quantitative dose maps from ^{90}Y PET data (4) can act as an early indicator of response to SIRT, if dose-response thresholds are known, and may be an indicator for concurrent alternative therapy targeting those lesions which are under-dosed. In particular, ^{90}Y dose maps play an integral part in the safe guiding of further SIRT procedures, where healthy liver parenchyma is at risk of further radiation insult and the development of REILD. A recent report by Bailey et al suggested that mCRC lesions may require a minimum average absorbed dose of at least 30 Gy (5) to reach a significant response, whilst a large prospective study from van den Hooven et al (6) established a dose of 40-60 Gy as the minimum required effective tumour absorbed dose. In terms of the response of normal liver parenchyma to radiation from SIRT procedures, it is speculated that due to the microscopic heterogeneity of the dose in healthy liver (7), a higher absorbed dose may be tolerated than previously thought when compared to external beam radiotherapy uniform dose fields. However, the literature lacks a uniform approach to measures of radionuclide dosimetry and response, and a large scale study would assist in establishing reliable thresholds that may be used to guide treatment planning.

Acknowledgements

Kathy Willowson is funded through an ARC

Linkage Grant in collaboration with Sirtex.

References

1. Sirtex Medical Limited: SIR-Spheres package insert. 2014.
2. Gil-Alzugaray B, Chopitea A, Inarrairauequi M, Bilbao JI, Rodriguez-Fraile M, Rodriguez J, et al. Prognostic factors and prevention of radioembolization-induced liver disease. *Hepatology*. 2013;57:1078-87.
3. Lhommel R, Goffette P, Van Den Eynde M, Jamar F, Pauwels S, Bilbao JI, et al. Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT. *Eur J Nucl Med Mol Imaging*. 2009;36:1696.
4. Willowson K, Tapner M, Bailey DL. The QUEST study: Correlating metabolic response with ^{90}Y PET dosimetry for the treatment of metastatic liver cancer with radioembolisation. *Eur J Nucl Med Mol Imaging*. 2015;41:S240.
5. Bailey DL, Willowson KP, Bernard EJ, Chan D, Pavlakis N, Clarke S. Preliminary direct evidence of a dose-response relationship for ^{90}Y -microsphere selective internal radionuclide therapy (SIRT) in hepatic malignancy. *J Clin Oncol*. 2015;33 (suppl; abstract 11064).
6. Van den Hoven AF, Rosenbaum CENM, Elias SG, De Jong H, Koopman M, verkooijen H, et al. Insights into the dose-response relationship of radioembolization with resin ^{90}Y -microspheres: A prospective cohort study in patients with colorectal cancer liver metastases. *J Nucl Med*. 2016;57:1014-9.
7. Walrand S, Hesse M, Jamar F, Lhommel R. A hepatic dose-toxicity model opening the way toward individualized radioembolization planning. *J Nucl Med*. 2014;55:1-6.